DocMorris AG / Analyst ratings
Price targets
Analyst ratings
5 analysts rated this company in the past 90 days. The average target price is €11.29, this is a change of +64.7% compared to the current price.
-
Jefferies maintains DocMorris 'Buy' - target CHF 12
NEW YORK (dpa-AFX Analyser) - The analysis house Jefferies has left the rating for DocMorris at "Buy" with a price target of 12 francs after a meeting with the head of the online pharmacy. Financial discipline is an important issue for the CEO, wrote Martin Comtesse in a study released Wednesday, also with a view to the ambitious earnings targets for 2026 and 2027./rob/mis/tih
Publication of the original study: September 10, 2025 / 8:57 a.m. / Time zone not specified in the study
First distribution of the original study: September 10, 2025 / 8:57 a.m. / Time zone not specified in the study
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Jefferies maintains DocMorris 'Buy' - target CHF 12
NEW YORK (dpa-AFX Analyser) - The analyst firm Jefferies has maintained its "Buy" rating for DocMorris with a price target of CHF 12. After a strong recovery in user numbers for e-prescriptions in July, these were subdued in August, wrote Martin Comtesse in a study released Wednesday. At DocMorris, the number of active users fell by 3 percent compared to the previous month, and app downloads fell by 5 percent. For counterparty Redcare Pharmacy, the decline even amounts to 9 and 13 percent, respectively./bek/niw
Publication of the original study: September 3, 2025 / 10:40 a.m. / ET
First distribution of the original study: September 3, 2025 / 10:40 a.m. / ET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Jefferies lowers DocMorris target to CHF 12 - 'Buy'
NEW YORK (dpa-AFX Analyst) - The analyst firm Jefferies has lowered its price target for DocMorris from 15 to 12 francs, but maintained its "Buy" rating. After the prolonged underperformance of shares of mid-sized European companies, the experts explore the opportunities in their analysis published Thursday. The German government investment package and a possible ceasefire in Ukraine provide a good basis for a reassessment of growth sectors and cyclical companies. However, they slightly reduced their cash flow expectations for the online pharmacy DocMorris./ag/mis
Publication of the original study: August 27, 2025 / 1:52 PM / ET
First distribution of the original study: August 27, 2025 / 7:00 PM / ET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Deutsche Bank maintains DocMorris on 'Hold' - target 8 francs
FRANKFURT (dpa-AFX Analyst) - Deutsche Bank Research has maintained its "Hold" rating for DocMorris following its quarterly results, with a price target of CHF 8. The online pharmacy's revenue missed the consensus estimate, wrote Jan Koch in a study published Wednesday. In addition, the prescription drug business in Germany performed worse than expected./edh/tih
Publication of the original study: August 20, 2025 / Time not specified in study / CET
First distribution of the original study: August 20, 2025 / 7:55 a.m. / CET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Jefferies maintains DocMorris at 'Buy' - target 15 francs
NEW YORK (dpa-AFX Analyst) - Following the release of earnings, analyst Jefferies has maintained a "buy" rating on DocMorris with a price target of CHF 15. The mail-order pharmacy once again missed expectations in the e-prescription segment in another weak quarter, Martin Comtesse wrote in his reaction on Tuesday. Although the adjusted operating result (EBITDA) declined as forecast, the Swiss company would have to significantly improve in the second half of the year to achieve the confirmed target range for 2025./rob/gl/edh
Publication of the original study: August 19, 2025 / 2:37 a.m. / CEST. First distribution of the original study: August 19, 2025 / 2:37 a.m. / CEST.
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
UBS maintains DocMorris on 'Sell' - target 8 francs
ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained a "sell" rating on DocMorris following the mail-order pharmacy's quarterly results, with a price target of CHF 8. The missed expectations for sales and net income are likely to weigh on the share price, although the confirmed outlook should limit the extent of the negative reaction, Sebastian Vogel wrote in an initial reaction on Tuesday./rob/gl/edh
Publication of the original study: August 19, 2025 / 05:44 / GMT First distribution of the original study: August 19, 2025 / Time not specified in study / Time zone not specified in study
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Baader Bank maintains DocMorris on 'Add' - target 10 francs
MUNICH (dpa-AFX Analyst) - Baader Bank has maintained its "Add" rating on DocMorris following the mail-order pharmacy's half-year results with a price target of CHF 10. Sales were slightly below its forecast and consensus estimate, primarily due to the German business, Volker Bosse wrote in a response released Tuesday. Currency-adjusted sales momentum lagged significantly behind that of competitor Redcare Pharmacy. In contrast, adjusted operating profit (EBITDA) narrowly exceeded expectations, and the Swiss company confirmed its annual targets./rob/gl/edh
Publication of the original study: August 19, 2025 / 7:57 a.m. / CEST. First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study.
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Jefferies maintains DocMorris at 'Buy' - target 15 francs
NEW YORK (dpa-AFX Analyser) - The analyst firm Jefferies has maintained a "Buy" rating on DocMorris, with a price target of CHF 15, following July data on e-prescriptions and app usage. The two mail-order pharmacies, DocMorris and Redcare, recorded strong month-on-month growth, wrote Martin Comtesse in a study published Tuesday. He attributes this primarily to increased marketing, especially in light of the recent ruling by the European Court of Justice regarding the granting of bonuses or vouchers for redeeming e-prescriptions. However, the market remains skeptical about DocMorris' confirmed sales target for e-prescriptions, he wrote, with a view to the half-year figures due on August 19./ck/tih
Publication of the original study: August 4, 2025 / 12:36 PM / ET
First distribution of the original study: August 4, 2025 / 7:00 PM / ET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Jefferies maintains DocMorris at 'Buy' - target 15 francs
NEW YORK (dpa-AFX Analyst) - The analyst firm Jefferies has maintained its "Buy" rating for DocMorris with a price target of CHF 15. Martin Comtesse evaluated the June user data for e-prescriptions in Germany on Thursday. According to the expert, this confirmed the sluggish signals regarding activity and app downloads from last week's quarterly key figures. From his perspective, this is the beginning of the summer slump./ag/gl
Publication of the original study: July 10, 2025 / 4:53 p.m. / ET First distribution of the original study: July 10, 2025 / 7:00 p.m. / ET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Jefferies maintains DocMorris at 'Buy' - target 15 francs
NEW YORK (dpa-AFX Analyst) - The analyst firm Jefferies has maintained its rating for DocMorris at "Buy" with a price target of CHF 15. There was no recovery in May, Martin Comtesse wrote on Tuesday regarding the latest data on e-prescriptions. User activity remains subdued in this regard./ag/tih
Publication of the original study: June 3, 2025 / 2:15 p.m. / Time zone not specified in the study
First distribution of the original study: June 3, 2025 / 7:00 p.m. / Time zone not specified in the study
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Baader Bank raises DocMorris to 'Add' - New target 10 francs
MUNICH (dpa-AFX Analyst) - Baader Bank has upgraded DocMorris from "Reduce" to "Add" due to the online pharmacy's improved financial stability. Volker Bosse wrote in a study published Tuesday that he adjusted the price target from 19 to 10 francs due to the increase in the number of shares following the successfully completed capital increase./rob/edh/gl
Publication of the original study: June 3, 2025 / 1:52 p.m. / CEST. First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study.
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Hauck Aufhäuser IB quarters DocMorris target after capital increase
HAMBURG (dpa-AFX Analyst) - Hauck Aufhäuser Investment Banking has adjusted its price target for DocMorris from 60 to 15 francs following a capital increase and maintained the rating at "Buy." Subscription rights were almost completely exercised, demonstrating strong shareholder support, and the number of shares outstanding has increased from just under 15 to 51 million, Christian Salis wrote in his reassessment published on Tuesday. The online pharmacy is now well positioned to drive expansion in the e-prescription sector. The expert expects DocMorris to achieve double-digit annual sales growth rates and a significant margin improvement./rob/gl/edh
Publication of the original study: May 27, 2025 / 8:11 a.m. / Time zone not specified in the study. First distribution of the original study: May 27, 2025 / 8:18 a.m. / Time zone not specified in the study.
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Jefferies lowers DocMorris target to CHF 15 - 'Buy'
NEW YORK (dpa-AFX Analyst) - The analyst firm Jefferies has lowered its price target for DocMorris from 39 to 15 francs, but maintained its "Buy" rating. Following the quarterly reports, Martin Comtesse adjusted his estimates for many mid-sized companies in German-speaking countries in his analysis published on Monday. The reports were generally weak, but most stocks are doing well this year given Germany's investment plans. He believes investors should take advantage of opportunities to reduce their exposure to the US and increase their exposure to Europe. He prefers locally oriented companies with independent supply chains. At DocMorris, he included dilution from a capital increase in his model./tih/ag
Publication of the original study: May 23, 2025 / 3:29 PM / ET
First distribution of the original study: May 25, 2025 / 8:00 AM / ET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Baader Bank maintains DocMorris on 'Reduce' - target 19 francs
MUNICH (dpa-AFX Analyst) - Baader Bank has maintained its rating for DocMorris at "Reduce" with a price target of CHF 19. Volker Bosse wrote in a study published Thursday that the dilution of earnings from the online pharmacy's capital increase was significantly greater than he expected. After completion of the capital increase, there should be 51 million shares./rob/bek/ajx
Publication of the original study: May 8, 2025 / 8:55 a.m. / CEST
First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Baader Bank lowers DocMorris to 'Reduce' and targets CHF 19
MUNICH (dpa-AFX Analyst) - Baader Bank has downgraded DocMorris from "Add" to "Reduce" and lowered its price target from CHF 44 to CHF 19. Analyst Volker Bosse justified this in a study published Wednesday, citing the significant dilution effects of a capital increase. He also stated that the forecast for the current year was disappointing. The online pharmacy has decided to invest more in marketing to capitalize on the potential associated with the introduction of e-prescriptions in Germany.
Publication of the original study: April 16, 2025 / 2:49 PM / CEST. First distribution of the original study: Date not specified in study / Time not specified in study / CEST.
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Deutsche Bank Research maintains a 'Hold' rating on DocMorris
FRANKFURT (dpa-AFX Analyst) - Deutsche Bank Research has maintained a "Hold" rating on DocMorris with a price target of CHF 20. According to reports, most investors are reassured that the online pharmacy has secured a CHF 200 million capital increase, analyst Jan Koch wrote in a commentary published Tuesday. However, many were hesitant to invest due to the significant dilution involved. The company still needs to prove that it can benefit from the German e-prescription market, where it clearly lags behind its competitor Redcare.
Publication of the original study: April 15, 2025 / 8:17 a.m. / CET. First distribution of the original study: Date not specified in study / Time not specified in study / CET.
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Warburg Research lowers target for DocMorris to CHF 19 - 'Hold'
HAMBURG (dpa-AFX Analyst) - The analyst firm Warburg Research has lowered its price target for DocMorris from CHF 33 to CHF 19 and maintained its "Hold" rating. A weak outlook for 2025 and significant dilution effects due to a capital increase would have resulted in lower estimates, analyst Michael Heider wrote in a study published Monday. The expert suspects that the new shares from the online pharmacy's capital increase will be placed at CHF 13 per share./bek/la
Publication of the original study: April 14, 2025 / 8:15 a.m. / CEST
First distribution of the original study: April 14, 2025 / Time not specified in the study / CEST
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Warburg Research maintains DocMorris on 'Hold' - Target CHF 33
HAMBURG (dpa-AFX Analyst) - The analyst firm Warburg Research has maintained its "Hold" rating for DocMorris following the company's earnings release, with a price target of CHF 33. The pharmaceutical retailer's first quarter was in line with market expectations, analyst Michael Heider wrote in a quick assessment released Thursday. The new annual outlook fell short of expectations. The planned capital increase, meanwhile, will lead to massive dilution./mf/nas
Publication of the original study: April 10, 2025 / 8:15 a.m. / CEST
First distribution of the original study: Date not specified in study / Time not specified in study / CEST
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Baader Bank maintains DocMorris at 'Add' - target 44 francs
MUNICH (dpa-AFX Analyst) - Baader Bank has maintained its rating for DocMorris at "Add" following the first-quarter figures, with a price target of CHF 44. The online pharmacy's sales met expectations, wrote analyst Volker Bosse in an initial reaction on Thursday. However, the targets for the current year are weak./bek/nas
Publication of the original study: April 10, 2025 / 7:59 a.m. / CEST
First distribution of the original study: April 10, 2025 / Time not specified in study / CEST
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Jefferies maintains DocMorris at 'Buy' - target 39 francs
NEW YORK (dpa-AFX Analyst) - Following first-quarter results, analyst Jefferies maintained its "Buy" rating for DocMorris with a price target of CHF 39. The online pharmacy had a slow start to the year, analyst Martin Comtesse wrote in an initial assessment on Thursday. However, new medium-term targets could restore optimism./bek/nas
Publication of the original study: April 10, 2025 / 2:02 AM / ET
First distribution of the original study: April 10, 2025 / 2:02 AM / ET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Jefferies maintains DocMorris at 'Buy' - target 39 francs
NEW YORK (dpa-AFX Analyser) - The analysis house Jefferies has left the rating for DocMorris at "Buy" with a price target of 39 francs after evaluating current e-prescription usage data. In addition to the upcoming key figures for the first quarter, analyst Martin Comtesse cited further statements by DocMorris regarding the planned capital increase as key price drivers in a study published Thursday./tih/edh
Publication of the original study: April 3, 2025 / 6:57 a.m. / ET
First distribution of the original study: April 3, 2025 / 6:57 a.m. / ET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Berenberg lowers target for DocMorris to CHF 17 - 'Hold'
HAMBURG (dpa-AFX Analyst) - Private bank Berenberg has lowered its price target for DocMorris from CHF 24 to CHF 17, but maintained its "Hold" rating. The proposed capital increase will have a massive dilution effect on existing shareholders, analyst Gerhard Orgonas wrote in his commentary published on Wednesday. On the other hand, the online pharmacy could use this to solve its refinancing problems and make necessary investments in the growth of its prescription business./ag/edh
Publication of the original study: March 18, 2025 / 5:25 PM / GMT
First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Deutsche Bank Research maintains a 'Hold' rating on DocMorris
FRANKFURT (dpa-AFX Analyst) - Deutsche Bank Research has maintained a "Hold" rating on DocMorris with a price target of CHF 25. The online pharmacy's final quarterly figures were in line with the previously published key figures, wrote analyst Jan Koch in an assessment released Friday. The now planned capital increase, about which DocMorris intends to provide more information with the financial results due on April 10, is slightly higher than expected at a possible CHF 200 million./gl/edh
Publication of the original study: March 14, 2025 / 8:10 a.m. / CET First distribution of the original study: Date not specified in study / Time not specified in study / CET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
UBS maintains DocMorris at 'Sell' - target 16 francs
ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its rating for DocMorris at "Sell" after the company's annual results, with a price target of CHF 16. Adjusted operating profit (EBITDA) is in line with targets and expectations, wrote analyst Sebastian Vogel in a study released Thursday. However, given the capital increase plans announced at the same time, he expects a negative price reaction./tih/gl
Publication of the original study: March 13, 2025 / 7:02 a.m. / GMT First distribution of the original study: March 13, 2025 / 7:02 a.m. / GMT
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Baader Bank maintains DocMorris at 'Add' - target 44 francs
MUNICH (dpa-AFX Analyst) - Baader Bank has maintained its rating for DocMorris at "Add" after final figures with a price target of CHF 44. In a study published Thursday, analyst Volker Bosse pointed to, among other things, an announced capital increase and a vague outlook for 2025. With regard to e-prescriptions, he mentioned that after the successful launch campaign, the online pharmacy is now moving on to "the next level of strategic communication."
Publication of the original study: March 13, 2025 / 8:01 a.m. / CET First distribution of the original study: Date not specified in study / Time not specified in study / CET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Jefferies maintains DocMorris at 'Buy' - target 39 francs
NEW YORK (dpa-AFX Analyst) - The research firm Jefferies has maintained its "Buy" rating for DocMorris with a price target of CHF 39. In February, the number of active users and app downloads saw significant growth for the first time since the summer, analyst Martin Comtesse wrote on Monday evening after analyzing the data. Redcare continued its strong growth with increases of 14 and 12 percent, respectively. DocMorris, on the other hand, recorded a decline compared to the previous month. Reduced marketing and a strained balance sheet were noticeable here. In light of the recent ECJ ruling on discounts, Comtesse sees the current practices of both online pharmacies as being substantiated./ag/zb
Publication of the original study: March 3, 2025 / 11:17 AM / ET
First distribution of the original study: March 3, 2025 / 7:00 PM / ET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Hauck Aufhäuser IB maintains DocMorris at 'Buy' - target 60 francs
HAMBURG (dpa-AFX Analyst) - Following a ruling by the European Court of Justice (ECJ) regarding bonuses on prescription drugs, Hauck Aufhäuser Investment Banking has maintained its rating for DocMorris at "Buy" with a price target of CHF 60. Analyst Christian Salis noted in a study released Friday that certain promotional measures involving vouchers could be banned if they could also be redeemed for over-the-counter medications. But even more importantly, this would not apply to discounts on the purchase of other prescription drugs./tih/gl
Publication of the original study: February 28, 2025 / 7:40 a.m. / CET. First distribution of the original study: February 28, 2025 / 8:02 a.m. / CET.
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
UBS lowers target for DocMorris to CHF 16 - 'Sell'
ZURICH (dpa-AFX Analyst) - Swiss bank UBS has lowered its price target for DocMorris from 25 to 16 francs and maintained its rating at "sell." After more than a year of e-prescriptions in Germany, he expects the online pharmacy's sales to continue to benefit, wrote analyst Sebastian Vogel in an assessment released Friday. However, given the persistently tough competition and unexpectedly slow changes in consumer habits, he has revised his assumptions for online pharmacies' market share in Germany downward. Due to the scale-dependent business model, Vogel also reduced its estimates for DocMorris' adjusted operating profit (EBITDA) and earnings per share./gl/ag
Publication of the original study: February 7, 2025 / 4:36 a.m. / GMT First distribution of the original study: February 7, 2025 / 4:36 a.m. / GMT
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Jefferies maintains DocMorris at 'Buy' - target 39 francs
NEW YORK (dpa-AFX Analyst) - The research firm Jefferies has maintained its "Buy" rating for DocMorris with a price target of CHF 39. After a weak end to the year, the number of active users saw a clear recovery in January, wrote analyst Martin Comtesse in his commentary published on Tuesday. The number even topped the October high. Downloads of the online pharmacy's apps also increased significantly. This development is encouraging for the recently relatively weak shares of Redcare and DocMorris./ag/gl
Publication of the original study: February 3, 2025 / 1:37 a.m. / ET. First distribution of the original study: February 3, 2025 / 7:00 p.m. / ET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Warburg Research lowers target for DocMorris to CHF 33 - 'Hold'
HAMBURG (dpa-AFX Analyst) - The analyst firm Warburg Research has lowered its price target for DocMorris from CHF 50 to CHF 33, but maintained its "Hold" rating. Analyst Michael Heider adjusted his valuation model in his commentary on the online pharmacy's preliminary sales figures published Wednesday./ag/tih
Publication of the original study: January 29, 2025 / 8:15 a.m. / CET
First distribution of the original study: Date not specified in study / Time not specified in study / CET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Hauck Aufhäuser IB maintains DocMorris at 'Buy' - target 60 francs
HAMBURG (dpa-AFX Analyst) - Hauck Aufhäuser Investment Banking has maintained its rating for DocMorris at "Buy" with a price target of CHF 60. The solid start to the new year gives hope that the trend can be reversed in the first quarter, wrote analyst Christian Salis in his commentary on key figures for the mixed fourth quarter, published Wednesday./ag/ajx
Publication of the original study: January 22, 2025 / 8:18 a.m. / CET
First distribution of the original study: January 22, 2025 / 8:18 a.m. / CET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Berenberg lowers target for DocMorris to CHF 24 - 'Hold'
HAMBURG (dpa-AFX Analyst) - Private bank Berenberg has lowered its price target for DocMorris from 36 to 24 francs, but maintained its "Hold" rating. Sales momentum was disappointing, wrote analyst Gerhard Orgonas in his commentary on the online pharmacy's quarterly update published Wednesday./ag/ck
Publication of the original study: January 21, 2025 / 4:45 p.m. / GMT
First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
UBS maintains DocMorris at 'Sell' - target 25 francs
ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its rating for DocMorris at "Sell" with a price target of CHF 25. The online pharmacy narrowly missed expectations overall, analyst Sebastian Vogel wrote on Tuesday after key figures. However, the prescription business clearly disappointed./ag/ajx
Publication of the original study: January 21, 2025 / 6:41 a.m. / GMT
First distribution of the original study: January 21, 2025 / 6:41 a.m. / GMT
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Jefferies lowers DocMorris target to CHF 39 - 'Buy'
NEW YORK (dpa-AFX Analyst) - The analyst firm Jefferies has lowered its price target for DocMorris from CHF 65 to CHF 39, but maintained its "Buy" rating. In their analysis published Monday, the experts focused on the opportunities for medium-sized European companies (midcaps). After four years of below-average performance, they now see more favorable conditions. Since they do not anticipate a "hard landing" of the global economy, they see enormous valuation potential, especially for cyclical stocks. They again significantly cut their medium-term estimates for the online pharmacy DocMorris. However, they emphasize that the discount to Redcare has reached a record level, with a view to maintaining their recommendation./ag/zb
Publication of the original study: January 12, 2025 / 1:53 PM / ET
First distribution of the original study: January 12, 2025 / 7:00 PM / ET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Berenberg maintains DocMorris on 'Hold' - target 36 francs
HAMBURG (dpa-AFX Analyst) - Private bank Berenberg has maintained a "Hold" rating on DocMorris with a price target of CHF 36. The online pharmacy's new CFO shared his initial impressions of the company and explained his focus on protecting cash in the coming months, analyst Gerhard Orgonas wrote in his commentary released Thursday following a meeting at the Berenberg investor conference.
Publication of the original study: December 4, 2024 / 10:42 a.m. / GMT First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
UBS maintains DocMorris at 'Sell' - target 25 francs
ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its rating for DocMorris at "sell" with a price target of CHF 25. Analyst Olivier Calvet regularly analyzed the app usage and download figures, as well as the prices of online pharmacies in the German market, on Monday evening. Current data shows further price investments by Redcare and fewer such measures at DocMorris, according to Calvet. Furthermore, there is lower app activity among the Swiss company. Overall, they would be further left behind by Redcare./ag/tih
Publication of the original study: November 11, 2024 / 6:30 p.m. / GMT
First distribution of the original study: November 12, 2024 / Time not specified in the study / GMT
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Hauck Aufhäuser IB maintains DocMorris at 'Buy' - target 60 francs
HAMBURG (dpa-AFX Analyst) - Hauck Aufhäuser Investment Banking has maintained its rating for DocMorris at "Buy" with a price target of CHF 60. Analyst Christian Salis drew a positive conclusion from a roadshow in his commentary published on Wednesday. A prescription bonus likely remains legal in light of recent news, which supports his growth estimates./ag/mis
Publication of the original study: October 30, 2024 / 8:32 a.m. / CET
First distribution of the original study: October 30, 2024 / 8:32 a.m. / CET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Jefferies maintains DocMorris at 'Buy' - target CHF 65
NEW YORK (dpa-AFX Analyst) - The research firm Jefferies has maintained a "Buy" rating on DocMorris with a price target of CHF 65. Analyst Martin Comtesse, in a study released Thursday, referred to the landmark case regarding price discounts on prescription drugs. A general counsel has issued a final opinion in the proceedings in which DocMorris is competing against the North Rhine Chamber of Pharmacists. This opinion clearly supports bonuses on prescription drugs. According to Comtesse, the final outcome is likely to have a significant impact on the future growth of online pharmacies. According to the expert, the final ruling from the European Court of Justice is expected in the next two to three months./tih/ajx
Publication of the original study: October 24, 2024 / 6:52 a.m. / ET First distribution of the original study: October 24, 2024 / 6:52 a.m. / ET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Deutsche Bank maintains DocMorris on 'Hold' - target 45 francs
FRANKFURT (dpa-AFX Analyst) - Deutsche Bank Research has maintained its rating for DocMorris at "Hold" with a price target of CHF 45 following an interim report on the third quarter. The online pharmacy's revenue remained slightly below the consensus estimate, wrote analyst Jan Koch in a study published Wednesday./edh/bek
Publication of the original study: October 16, 2024 / Time not specified in study / CET
First distribution of the original study: October 16, 2024 / 08:02 / CET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Jefferies maintains DocMorris at 'Buy' - target CHF 65
NEW YORK (dpa-AFX Analyst) - Following the online pharmacy's quarterly figures, analyst firm Jefferies has maintained its "Buy" rating for DocMorris with a price target of CHF 65. The e-prescription business in Germany increased significantly compared to the previous quarter, but remains moderate – especially compared to competitor Redcare, wrote analyst Martin Comtesse in a study released Tuesday. Although most of the negative news has been priced in since the profit warning in August, management must now prove that it can translate higher marketing expenditures into tangible sales growth./edh/bek
Publication of the original study: October 15, 2024 / 1:54 AM / ET
First distribution of the original study: October 15, 2024 / 1:54 AM / ET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Warburg Research maintains DocMorris on 'Hold' - target 50 francs
HAMBURG (dpa-AFX Analyser) - The analyst firm Warburg Research has maintained its "Hold" rating for DocMorris following its quarterly results, with a price target of CHF 50. The online pharmacy's sales were in line with its forecast, wrote analyst Michael Heider in a study released Tuesday. Overall, however, the key figures show that the Swiss company is clearly losing market share to its German competitor Redcare./edh/bek
Publication of the original study: October 15, 2024 / 8:15 a.m. / CEST
First distribution of the original study: Date not specified in study / Time not specified in study / CEST
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Hauck Aufhäuser IB maintains DocMorris at 'Buy' - target 60 francs
HAMBURG (dpa-AFX Analyst) - Hauck Aufhäuser Investment Banking has maintained its "Buy" rating for DocMorris following the online pharmacy's quarterly figures, with a price target of CHF 60. Competitor Redcare is currently clearly outperforming DocMorris, which is due to the German company's stronger marketing power, wrote analyst Christian Salis in a study released Tuesday. Nevertheless, the accelerated growth in sales of e-prescriptions in Germany shows that the Swiss marketing investments are increasingly paying off./edh/bek
Publication of the original study: October 15, 2024 / 8:20 a.m. / CEST
First distribution of the original study: October 15, 2024 / 8:21 a.m. / CEST
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Baader Bank maintains DocMorris at 'Add' - target 44 francs
MUNICH (dpa-AFX Analyst) - Baader Bank has maintained its rating for DocMorris at "Add" with a price target of CHF 44 following the third-quarter results. Sales momentum in the prescription drug business on the German market has increased, wrote analyst Volker Bosse in an initial assessment on Tuesday. In recent weeks, growth has been more than a quarter higher than in the same period last year./bek/ajx
Publication of the original study: October 15, 2024 / 7:49 a.m. / CEST
First distribution of the original study: October 15, 2024 / Time not specified in study / CEST
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
UBS maintains DocMorris at 'Sell' - target 27 francs
ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its rating for DocMorris at "Sell" with a price target of CHF 27 following third-quarter results. The online pharmacy's sales are roughly in line with expectations, wrote analyst Sebastian Vogel in an initial reaction on Tuesday. He expects a slightly negative share price reaction, as DocMorris appears to be falling further behind its leading German competitor in the prescription drug business./bek/ajx
Publication of the original study: October 15, 2024 / 05:21 / GMT
First distribution of the original study: October 15, 2024 / 05:21 / GMT
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Berenberg lowers DocMorris to 'Hold' - target down to CHF 36
HAMBURG (dpa-AFX Analyst) - Private bank Berenberg has downgraded DocMorris from "Buy" to "Hold" and lowered its price target from CHF 125 to CHF 36. According to his analysis published Wednesday, Gerhard Orgonas is now significantly more skeptical about the Swiss company's e-prescription business than he was when he issued his buy recommendation in January. He expects structurally lower growth in prescription sales and fears market share losses./ag/zb
Publication of the original study: October 8, 2024 / 4:11 PM / GMT
First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Jefferies maintains DocMorris at 'Buy' - target CHF 65
NEW YORK (dpa-AFX Analyst) - The research firm Jefferies has maintained its "Buy" rating for DocMorris with a price target of CHF 65. In September, thanks to more intensive marketing, online pharmacies saw a clear upturn, and the summer lull is over, wrote analyst Martin Comtesse in his e-prescription data tracker for the German market, published Wednesday. Since July, Redcare Pharmacy, in particular, has gained significant momentum. App downloads showed a similar picture.
Publication of the original study: October 8, 2024 / 3:59 PM / ET. First distribution of the original study: October 8, 2024 / 7:00 PM / ET.
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Jefferies maintains DocMorris at 'Buy' - target CHF 65
NEW YORK (dpa-AFX Analyst) - Following a discussion with CEO Walter Hess, analyst Jefferies has maintained its rating for DocMorris at "Buy" with a price target of CHF 65. According to Hess, business development since the introduction of an e-prescription redemption process has painted a promising picture, wrote analyst Martin Comtesse in a study published Friday. DocMorris is confident it can achieve its medium-term goals in Germany. It is assumed that current cash reserves are sufficient to reach the break-even point without additional capital injections./tih/la
Publication of the original study: September 20, 2024 / 8:30 a.m. / ET
First distribution of the original study: September 20, 2024 / 8:30 a.m. / ET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
UBS maintains DocMorris at 'Sell' - target 27 francs
ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its rating for DocMorris at "Sell" with a price target of CHF 27. Analyst Olivier Calvet evaluated current app usage and pricing data in his commentary on online pharmacies published Friday. DocMorris slightly reduced its pricing initiatives after a strong push in July, while Redcare showed a significant marketing push in August. App usage at DocMorris remains relatively low./tih/ag
Publication of the original study: September 19, 2024 / 5:00 PM / GMT
First distribution of the original study: September 19, 2024 / 5:00 PM / GMT
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
UBS maintains DocMorris at 'Sell' - target 27 francs
ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its rating for DocMorris at "Sell" with a price target of CHF 27 following an investor event. The online pharmacy reported an improving market share for e-prescriptions, analyst Sebastian Vogel wrote in a study released Wednesday. However, it remains to be seen whether German customers will use e-prescriptions for prescription drugs./bek/nas
Publication of the original study: September 11, 2024 / 4:58 PM / GMT
First distribution of the original study: September 11, 2024 / 4:58 PM / GMT
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Baader Bank lowers target for DocMorris to CHF 44 - 'Add'
MUNICH (dpa-AFX Analyst) - Baader Bank has lowered its price target for DocMorris from CHF 100 to CHF 44, but left the rating at "Add." Analyst Volker Bosse cut his sales and earnings estimates for the online pharmacy on Tuesday. He justified his unchanged positive assessment with the enormous market potential and strong customer growth./ag/gl
Publication of the original study: September 10, 2024 / 12:05 / CEST. First distribution of the original study: Date not specified in study / Time not specified in study / CEST.
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Jefferies maintains DocMorris at 'Buy' - target CHF 65
NEW YORK (dpa-AFX Analyst) - Following August data on the German e-prescription service, analyst Jefferies has maintained its rating for DocMorris at "Buy" with a price target of CHF 65. Redcare, with its Shop Apotheke brand, is gaining momentum, as the online pharmacy regained the lead in monthly active users year-on-year in August, wrote analyst Martin Comtesse in a study released Wednesday. Compared to the previous month, growth at Redcare increased, but at DocMorris it declined slightly./tih/mis
Publication of the original study: September 3, 2024 / 6:56 PM / ET
First distribution of the original study: September 3, 2024 / 6:56 PM / ET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Jefferies lowers DocMorris target to CHF 65 - 'Buy'
NEW YORK (dpa-AFX Analyst) - The research firm Jefferies has lowered its price target for DocMorris from 110 to 65 francs, but maintained its rating at "Buy." In a study published Tuesday, analyst Martin Comtesse examines investment opportunities in small and medium-sized European companies, whose valuations—unlike those of large companies—are still as cheap as ever. While a broad-based recovery is still a long way off, interest rates in the eurozone have already begun to reverse the trend. With regard to DocMorris, he pointed to the announced increase in the online pharmacy's marketing budget in connection with the introduction of the German e-prescription system. Therefore, the operating break-even point is likely not to be reached until 2026. However, he believes the significant discount to competitor Redcare still justifies a buy recommendation./tih/ck
Publication of the original study: September 2, 2024 / 7:15 PM / ET
First distribution of the original study: September 2, 2024 / 7:16 PM / ET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
UBS maintains DocMorris at 'Sell' - target 27 francs
ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its rating for DocMorris at "sell" with a price target of CHF 27. A recent e-commerce survey reveals an unfavorable demand picture for the online pharmacy regarding shopping behavior in the mobile app, wrote analyst Sebastian Vogel in a study released Monday. He sees this as confirmation of his cautious assessment of the company's medium-term revenue prospects./tih/ck
Publication of the original study: September 1, 2024 / 7:49 a.m. / GMT
First distribution of the original study: September 1, 2024 / 7:49 a.m. / GMT
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Warburg Research lowers DocMorris to 'Hold' - target 50 francs
HAMBURG (dpa-AFX Analyst) - The analyst firm Warburg Research has downgraded DocMorris from "Buy" to "Hold" and lowered its price target from CHF 60 to CHF 50. Analyst Michael Heider justified his more negative assessment in a study released Monday with the online pharmacy's deteriorating profitability and growth targets. He was particularly surprised that DocMorris justified its reduced EBITDA target with higher marketing expenditures. These should normally lead to increased sales, but the company has also lowered its revenue target at the same time./edh/tih
Publication of the original study: August 26, 2024 / 8:15 a.m. / CEST
First distribution of the original study: Date not specified in study / Time not specified in study / CEST
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.